Navigation Links
New data on hormone therapy must lead to re-evaluation of official guidelines

As opinion leaders in the field of menopause medicine from various areas in the world, we wish to emphasize the following points concerning postmenopausal hormone therapy:

  1. Hormone therapy (HT) remains the most effective treatment for vasomotor symptoms and estrogen-deficient urogenital symptoms.

  2. The initial interpretation of the Womens Health Initiative (WHI) trial failed to recognize the immense importance of age and years since menopause on outcomes of HT. The potential impact of specific hormonal regimens on safety of HT should be considered as well.

  3. The results of the WHI trial were wrongly extrapolated to the whole postmenopausal population, which led to a major change in recommendations and guidelines on HT.

  4. Based on current knowledge, the balance between the benefits and risks of HT is clearly in favor of use in the early postmenopausal years for symptomatic, healthy women.

  5. All previous studies, including the WHI trial, have demonstrated significant positive effect on bone density and reduction in fracture risk among hormone users.

  6. Estrogen has favorable metabolic and cardioprotective effects in healthy, young postmenopausal women. The results for the age group 5059 years in the WHI estrogen-alone arm support this claim. Estrogen slows the pace of development of atherosclerosis if started in the early postmenopausal period.

  7. HT may be associated with a small increase in risk for breast cancer, if taken long term. Combined estrogenprogestogen therapy probably carries a higher risk than that recorded for estrogen alone. Prevalence of stroke and thromboembolism strongly correlates with age; therefore, the impact of the HT-related increased risk in this respect becomes more important in the late menopause. Low-dose estrogen or the transdermal route of administration may lead to a more favorable risk profile.

  8. Progestins, combined with estrogen, may decrease the magnitude of estrogen-related cardiac benefits, and increase the risk for breast cancer. There are insufficient data to evaluate the possible differences in the incidence of breast cancer using different types and routes of progestin administration.

Based on the above, we call upon the health authorities to review their policies and revise them in view of the new age-related data on HT. Also, the different outcomes of estrogen-alone and estrogen plus progestin therapy should be considered. Overall, the safety profile of HT until age 60 is favorable, and should not preclude women from using HT when appropriate. Issues of quality of life, including mental, emotional, cognitive and sexual function, should have a higher priority while discussing regulatory policies and official guidelines on postmenopausal HT use.


Contact: Jean Wright
International Menopause Society

Related medicine news :

1. Thyroid hormone treatment hastens recovery after cardiac surgery
2. Levothyroxine Thyroid Hormone Replacement, Approved for Hypothyroidism
3. Hormone replacement Therapy a headache
4. Ovarian cancer in relationship with Hormone therapy
5. Evaluating The Risks and Benefits of Hormone Therapy
6. Scientists crack mechanism of Leptin-Obesity Hormone
7. Scientists use plant hormones to fight cancer
8. Use parathyroid hormone to fight brittle bone disease
9. Multiple Sclerosis Can Be Treated By Blocking Fat Hormone
10. Hormone contraceptives lead to bone problems
11. Hormone treatment helps obese people slim down
Post Your Comments:
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are ... Code Talker Award, an essay contest in which patients and their families pay tribute ... presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty ... Barry M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... and the most handsome men, look naturally attractive. Plastic surgery should be invisible.” ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, ... economy by obtaining investment capital for emerging technology companies. SCP has delivered ... already resulted in more than a million dollars of capital investment for five ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) ... held on June 20th at the Woodmont Country Club at 1201 Rockville Pike, ... organization dedicated to helping service members that have been wounded in battle and their ...
(Date:6/24/2016)... ... June 24, 2016 , ... Advanced Plastic Surgery Institute ( ... as its official Medspa Sponsor. Dr. Josh Olson, a board-certified plastic surgeon, owns ... Dr. Olson says the decision to support the pageant in an official capacity ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
(Date:6/24/2016)... 2016 Research and Markets has announced ... Diagnostic Tests" report to their offering. ... The World Market for Companion Diagnostics covers ... Market analysis in the report includes the following: ... Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
Breaking Medicine Technology: